WALL STREET CHOICE: ABBOTT RATED A STRONG PICK ON HUMIRA DEMAND

Document Sample
WALL STREET CHOICE: ABBOTT RATED A STRONG PICK ON HUMIRA DEMAND Powered By Docstoc
					WALL STREET CHOICE: ABBOTT RATED A STRONG PICK ON HUMIRA DEMAND
Anonymous
Medical Marketing and Media; Nov 2008; 43, 11; Docstoc
pg. 34




Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

				
DOCUMENT INFO
Description: Abbott sees 2008 revenues reaching $30 billion, driven by continued strong demand for Humira in the rheumatology, dermatology and gastroenterology segments, contributions from cholesterol-lowering pharmaceuticals, modest growth in diagnostics and higher vascular sales on the recent launch of the Xience coronary stent in the US. The company anticipates that gross and operating margins will expand in 2008 and 2009, aided by cost efficiencies resulting from the integration of recent acquisitions and new product contributions. Risks to their recommendation and target price include lower-than-expected product sales, generic competition to Synthroid and Biaxin, and pipeline disappointments.
BUY THIS DOCUMENT NOW PRICE: $6.95 100% MONEY BACK GUARANTEED
PARTNER ProQuest LLC
ProQuest creates specialized information resources and technologies that propel successful research, discovery, and lifelong learning.